BioCentury

10:58 PM GMT, Sep 21, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Company News

Halozyme jumps after FDA lifts hold on subcutaneous Cinryze

Halozyme Therapeutics Inc. (NASDAQ:HALO) jumped $1.54 (24%) to $7.95 on Friday after it and partner ViroPharma Inc. (NASDAQ:VPHM)

Read the full 189 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.